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Although placebo contributes to the effects of treat-
ment for various symptoms and conditions, its
effect on itch has rarely been investigated. In this
meta-analysis, the magnitude of the placebo effect on
itch was systematically investigated in clinical trials
including patients with chronic itch due to atopic
dermatitis, psoriasis, or chronic idiopathic urticaria.
From searches in four databases, 34 articles were
included in the quantitative analyses. Placebo treat-
ment significantly decreased itch (1.3 out of 10, 95%
confidence interval 1.02–1.61) compared with baseline
itch (effect size 0.55), indicating that placebo effects
have a considerable role in these patients’ treatment.
Journal of Investigative Dermatology (2015) 135, 1234–1243;
doi:10.1038/jid.2014.522; published online 22 January 2015
INTRODUCTION
Placebo effects are known to contribute to the effects of
treatment for various conditions and symptoms (Benedetti,
2008). Placebo effects have been studied extensively with
respect to pain and other conditions––for example, in several
meta-analyses that reported on the analgesic effects of placebo
in clinical trials. Overall, effect sizes (ESs) vary largely across
studies and range from small to large (Vase et al., 2002;
Hrobjartsson and Gotzsche, 2004; Vase et al., 2009). The
magnitude of the analgesic effect of placebo mainly depends
on the study design, being largest in studies investigating
placebo mechanisms, when the expectations of pain relief are
optimized as much as possible and smaller when placebo
effects are minimized (Vase et al., 2009).
In contrast to pain, there is less research on the role of
placebo effects in the treatment of chronic itch, the most
common symptom of patients with skin disease. A substantial
proportion of patients with atopic dermatitis (AD), psoriasis
(PSO), and chronic idiopathic urticaria (URT), highly prevalent
skin conditions, experience chronic itch (Verhoeven et al.,
2007; Weisshaar and Dalgard, 2009; Sta¨nder et al., 2010). It
can adversely affect patients’ quality of life––e.g., patients
experience sleep disturbances, fatigue, and symptoms of
psychological distress, such as anxiety and depressive
symptoms (Schneider et al., 2006; Sta¨nder et al., 2010). The
effect of treatment often varies considerably between patients,
in which placebo effects may also have a role.
The effects of placebo on itch have barely been studied.
There is only limited experimental evidence, in line with what
is known of placebo effects on pain (Colloca et al., 2013), that
placebo (and nocebo) effects on itch can be induced
experimentally (Van Laarhoven et al., 2011; Bartels et al.,
2014). However, the role of placebo effects on itch in the
clinical setting has, to our knowledge, not yet been
investigated. Therefore the aim of this meta-analysis was to
investigate the magnitude of the effect of placebo on itch in
randomized controlled trials that investigated the itch-
reducing effects of regular pharmacological treatments in
highly prevalent chronic dermatological conditions with itch
as the main symptom, specifically patients with AD, PSO, or
URT. For the purpose of the present study, we were
particularly interested in the reduction in itch as evoked in
the placebo conditions of these trials. In line with placebo
effects on chronic pain, it was hypothesized that placebo
effects on itch would occur in clinical trials involving
dermatological patients with chronic itch.
RESULTS
Study selection
Of the 11,919 and 33 records retrieved from the initial search
in four databases and hand-searching, respectively, 5475
studies were duplicates, 6379 studies were excluded on the
basis of screening of the titles/abstracts, and 6 studies that
were relevant to read were not available full text (see
Supplementary Figure S1 online for the flow diagram of the
numbers of studies included in this meta-analysis). The
eligibility of 159 studies was assessed in full-text articles. Of
these, 89 studies were excluded for various reasons, i.e.,
because the study was not a randomized controlled trial
(n¼ 7), no (quantitative) itch scores were measured (mainly
PSO), or itch was measured as part of a combined score (e.g.,
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Dermatology Life Quality Index; n¼60), no patients (with a
relevant skin condition) were included or the patient sample
was unspecified (n¼9), 480% of the included patients had
another specific diagnosis in addition to the dermatological
condition of interest (n¼ 3), all patients started with a
concurrent treatment in addition to placebo (n¼3), itch was
induced after placebo administration and baseline measure-
ments were not possible (n¼ 2), the data had been published
previously (n¼3), or the study was published before 1970
(n¼ 2). Of the remaining 70 studies that were included in the
qualitative synthesis, 34 were included in the meta-analysis
because the required data were available.
Study characteristics
The characteristics of the reviewed studies (n¼70) are given
in Table 1. The review included 12 218 patients with a skin
disease, 4141 of whom were included in the placebo condi-
tions––namely, 502 with AD, 1864 with PSO, 1719 with URT,
and 56 with MIX (i.e., different dermatological conditions,
predominantly AD and URT). In 54 studies (77.1%), systemic
placebo treatment was administered orally (pills or solution),
in 15 studies (21.4%) by injection, and in 1 study (1.4%) by a
combination of both. Sixty-nine studies (98.6%) investigated
the effects on clinical itch; 1 study (1.4%) focused on itch-
inducing stimuli (Hosogi et al., 2006). Seventeen studies
(24%) had a cross-over design; the remaining 53 studies had
a parallel-group design (76%). Except for two single-blind
studies (Hosogi et al., 2006; Wan, 2009), all were double-
blind (97%). Study duration ranged from 1 day to 24 weeks.
Risk of bias within and across studies
The quality of the 70 included studies varied (see
Supplementary Figures S2 and S3 online for the authors’ risk
of bias assessment), and only 6 studies met all 6 validity
criteria and thus were of minimal risk of bias. Methods of
randomization were adequate in 37% of the studies, 59% did
not specify the randomization method, and 4% reported
inadequate methods. In 41% of the studies, allocation of
participants was adequately concealed, in 51% the conceal-
ment was unclear, and in 7% the concealment was inade-
quate––for example, the article did not report randomization
or the study was single-blind. Blinding of participants, per-
sonnel, and outcome assessors was rated low in 96% of the
studies because of the double-blind design, in 1% of the
studies it was unclear (i.e., the study was described as double-
blinded but reported inadequate allocation concealment
methods), whereas single-blind studies (3%) were character-
ized as having a high risk of bias. Incomplete outcome data
were scored low in 44% of the studies, unclear in 43%, and
high in 13% of the studies––e.g., when the reason for missing
outcome data was considered to be related to the outcome
and drop-outs were not included in the statistical analyses.
Selective reporting bias was scored low in 59% of the studies,
unclear in 39% of the studies, and high in 3% of the studies,
for the reason that the study did not predefine analyses or
failed to report primary outcomes for all evaluation moments.
With respect to other bias, in 54% of the studies there was a
low risk, in 30% of the studies there was insufficient
information to assess bias, and in 16% of the studies there
was high risk of other bias, mainly because of drop-out rates
440% of the baseline sample size.
Across the studies, there was a substantial heterogeneity,
with an overall I2 of 92%. Inspection of the funnel plot does
not indicate publication bias.
Placebo effects on itch
Figure 1 displays the forest plot of the random-effects meta-
analysis investigating the magnitude of placebo effects on itch
in clinical trials. Overall, there was a mean difference in itch
of 1.31 points on a scale from 0 to 10 (95% confidence
interval (CI) 1.02–1.61, I2¼92%), with lower levels of itch
being reported after placebo treatment than at baseline. This
equals a mean reduction of 24% of itch severity, considering
that the level of itch at baseline was on average 5.43. The
standardized mean difference analysis revealed an overall
moderate–large ES of 0.55 (95% CI 0.40–0.70, I2¼88%). The
mean decrease in itch in the studies that provided insufficient
information to be included in the meta-analysis, but for which
the relevant means were available (n¼ 14), was 1.59 on a
scale from 0 to 10.
Secondary analyses
For the individual dermatological conditions, the mean
decrease in itch within the placebo condition was 0.75
(95% CI 0.12–1.39, I2¼79%) for AD, 1.04 (95% CI 0.54–
1.53, I2¼88%) for PSO, and 1.71 (95% CI: 1.28–2.15,
I2¼ 93%) for URT, showing larger ES for URT 0.71 (95% CI
0.50–0.91, I2¼ 86%) and PSO 0.45 (95% CI 0.23–0.66,
I2¼ 86%) than for AD 0.30 (95% CI 0.05–0.56, I2¼64%).
The mean difference in itch was significant across conditions
(P¼ 0.03). There was no significant difference between the
effect of oral (mean difference 1.41; 95% CI 0.87–1.94,
I2¼ 94%) versus injected (mean difference 1.21; 95% CI
0.75–1.68, I2¼ 85%) placebo treatment (P¼ 0.60). In the
explorative analyses, which only included studies that were
published the past 20 (since 1994) and 10 years (since 2004),
the overall mean difference in itch was 1.49 (95% CI 1.19–
1.78, I2¼ 92%) and 1.70 (1.29–2.12, I2¼ 95%), respectively.
Sensitivity analyses
Sensitivity analyses testing the stability of the effects in relation
to the correlation coefficient imputed for the SDs at baseline
and at the end of placebo treatment (r¼ 0.5) yielded a
maximum variance of 2.2% of the main outcome (mean
difference in itch ranging from 1.32 to 1.38). Sensitivity
analyses after exclusion of the separate studies that had a
high risk of bias for one of the risk of bias categories resulted in
a maximum variance of 3.8% of the main outcome (mean
difference in itch ranging from 1.31 to 1.36; I2 range 92–93%).
Exclusion of all studies that had a high risk of bias in one of the
categories at once resulted in a mean decrease in itch of 1.57
(95% CI 1.23–1.92, I2¼ 93%). After exclusion of the small
studies (fewer compared with 25 patients in the placebo
condition; n¼15), the overall mean difference in itch was
1.47 (95% CI 0.99–1.94, I2¼95%), indicating that placebo
effects were smaller for the studies with smaller sample sizes.
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Table 1. Study and patient characteristics of randomized controlled trials comparing an itch-reducing agent with a placebo included in the meta-analysis
No. Studya
Sample size
placebo
(analyzed)b Gender
Category of active
treatment
Placebo
administration
route
Placebo
treatment
duration (weeks)
Study
design Blinding Origin of itch
Atopic dermatitis
1. Berth-Jones and Graham-Brown,
1989
28 (24) Unclear Antihistamine Oral 1 Cross-over Double-blind Clinical
2. Berth-Jones and Graham-Brown,
1990
50 (45) Mþ F Natural component of opium Oral 4 Cross-over Double-blind Clinical
3. Berth-Jones et al., 2002 28 (28)c Mþ F Immunomodulator Oral 12 Cross-over Double-blind Clinical
4. Ebata et al., 1998 10 (10) Mþ F Benzodiazepine Oral 1 Cross-over Double-blind Clinical
5. Friedmann et al., 2007 30 (29)c Mþ F Leukotriene receptor
antagonist
Oral 8 Parallel Double-blind Clinical
6. Frosch et al., 1984 18 (16) Mþ F Antihistamine Oral 4 Cross-over Double-blind Clinical
7. Hosogi et al., 2006 14 (14) Mþ F Antihistamine Oral 0.1 Cross-over Single-blind Experimental:
Histamine
8. Kavli and Larsen, 1981 Unclear (9) Mþ F Antihistamine Oral 12 Cross-over Double-blind Clinical
9. Leung et al., 1990 52 (45) Mþ F Immunomodulator Injection 6 Parallel Double-blind Clinical
10. Lintu et al., 2001 40 (39) Mþ F Anti-fungal Oral 4 Parallel Double-blind Clinical
11. Malekzad et al., 2009 20 (18) Mþ F Opioid receptor antagonist Oral 2 Parallel Double-blind Clinical
12. Meggitt et al., 2006 21 (20)c Mþ F Immunomodulator Oral 12 Parallel Double-blind Clinical
13. Munro et al., 1994 24 (10) Mþ F Immunomodulator Oral 8 Cross-over Double-blind Clinical
14. Oldhoff et al., 2005 23 (22) Mþ F Immunomodulator Injection 2 Parallel Double-blind Clinical
15. Pittler et al., 2003 15 (15)c Mþ F Autologous blood therapy Injection 5 Parallel Double-blind Clinical
16. Shupack et al., 1991 11 (unclear) Mþ F Natural component of opium Oral 2 Parallel Double-blind Clinical
17. Sowden et al., 1991 16 (12) Mþ F Immunomodulator Oral 8 Cross-over Double-blind Clinical
18. Stiller et al., 1994 19 (17) Mþ F Immunomodulator Injection 12 Parallel Double-blind Clinical
19. Van Joost et al., 1994 23 (23) Mþ F Immunomodulator Oral 6 Parallel Double-blind Clinical
20. Wahlgren et al., 1990a 24 (24) Mþ F Antihistamine Oral 1 Cross-over Double-blind Clinical
21. Wahlgren et al., 1990b 10 (10) Mþ F Immunomodulator Oral (solution) 10 Cross-over Double-blind Clinical
22. Wolff et al., 2005 26 (26)c Mþ F Immunomodulator Oral 12 Parallel Double-blind Clinical
Psoriasis
23. Bissonnette et al., 2006 41 (41)c Mþ F Immunomodulator Oral 12 Parallel Double-blind Clinical
24. Bushmakin et al., 2013 50 (34) Mþ F Immunomodulator Oral 12 Parallel Double-blind Clinical
25. Feldman et al., 2005 166 (166) Mþ F Immunomodulator Injection 12 Parallel Double-blind Clinical
26. Gordon et al., 2014 38 (38)c Mþ F Immunomodulator Oral 12 Parallel Double-blind Clinical
27. Gordon et al., 2003 187 (187)c Mþ F Immunomodulator Injection 12 Parallel Double-blind Clinical
28. Krueger et al., 2005 193 (193)c Mþ F Immunomodulator Injection 12 Parallel Double-blind Clinical
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Table 1. (Continued )
No. Studya
Sample size
placebo
(analyzed)b Gender
Category of active
treatment
Placebo
administration
route
Placebo
treatment
duration (weeks)
Study
design Blinding Origin of itch
29. Leonardi et al., 2012 27 (26)c Mþ F Immunomodulator Injection 16 Parallel Double-blind Clinical
30. Mamolo et al., 2013 50 (43)c Mþ F Immunomodulator Oral 12 Parallel Double-blind Clinical
31. Ortonne et al., 2005 264 (262) Unclear Immunomodulator Injection 12 Parallel Double-blind Clinical
32. Papp et al., 2012 88 (88)c Mþ F Immunomodulator Oral 16 Parallel Double-blind Clinical
33. Revicki et al., 2008 53 (53)c Mþ F BiologicþDMARD Oralþ Injection 16 Parallel Double-blind Clinical
34. Revicki et al., 2007 397 (347)c Mþ F Biologic Injection 16 Parallel Double-blind Clinical
35. Tyring et al., 2006 309 (307) Mþ F Immunomodulator Injection 1 Parallel Double-blind Clinical
Chronic idiopathic urticaria
36. Abu Shereeah et al., 1998 9 (8) Mþ F Antihistamine Oral 3 Parallel Double-blind Clinical
37. Bernstein and Bernstein, 1986 27 (24) Mþ F Antihistamine Oral 8 Parallel Double-blind Clinical
38. Breneman et al., 1995 63 (61) Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
39. Bressler et al., 1989 9 (7) Mþ F Calcium channel antagonist Oral 4 Cross-over Double-blind Clinical
40. Brostoff et al., 1996 28 (28)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
41. Camarasa et al., 2001 20 (18)c Mþ F Antihistamine Oral 3 Parallel Double-blind Clinical
42. Di Lorenzo et al., 2004 40 (5) Mþ F Antihistamineþ Leukotriene
receptor antagonist
Oral 6 Parallel Double-blind Clinical
43. Dubertret et al., 1999 80 (80)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
44. Dubertret et al., 2007 69 (69)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
45. Ferguson et al., 1985 Unclear (14) Mþ F Antihistamine Oral 2 Cross-over Double-blind Clinical
46. Finn et al., 1999 95 (90)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
47. Fox et al., 1986 26 (26)c Mþ F Antihistamine Oral 8 Parallel Double-blind Clinical
48. Gibson et al., 1984 20 (20) Mþ F Antihistamine Oral 0.7 Cross-over Double-blind Clinical
49. Gimenez-Arnau et al., 2007 111 (111)c Mþ F Antihistamine Oral 6 Parallel Double-blind Clinical
50. Goh et al., 1991 32 (28) Mþ F Antihistamine Oral 1 Cross-over Double-blind Clinical
51. Juhlin and Arendt, 1988 30 (30) Mþ F Antihistamine Oral 2 Cross-over Double-blind Clinical
52. Kailasam and Mathews, 1987 24 (23) Mþ F Antihistamine Oral 8 Parallel Double-blind Clinical
53. Kalivas et al., 1990 74 (68) Unclear Antihistamine Oral 4 Parallel Double-blind Clinical
54. Kaplan et al., 2013 84 (83)c Mþ F Immunomodulator Injection 12 Parallel Double-blind Clinical
55. Kaplan et al., 2005 92 (92)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
56. Kapp and Pichler, 2006 85 (85)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
57. Kosnik and Subic, 2011 24 (22) Mþ F Leukotriene receptor
antagonist
Oral 2 Cross-over Double-blind Clinical
58. Magerl et al., 2013 26 (26)c Mþ F Lipid raft modulator Oral 4 Parallel Double-blind Clinical
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Table 1. (Continued )
No. Studya
Sample size
placebo
(analyzed)b Gender
Category of active
treatment
Placebo
administration
route
Placebo
treatment
duration (weeks)
Study
design Blinding Origin of itch
59. Maurer et al., 2011 22 (22)c Mþ F Immunomodulator Injection 24 Parallel Double-blind Clinical
60. Maurer et al., 2013b 79 (79)c Mþ F Immunomodulator Injection 12 Parallel Double-blind Clinical
61. Monroe et al., 2003 110 (75)c Mþ F Antihistamine Oral 6 Parallel Double-blind Clinical
62. Nelson et al., 2000 79 (79)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
63. Pacor et al., 2001 17 (17) Mþ F Antihistamineþ Leukotriene
receptor antagonist
Oral 4 Parallel Double-blind Clinical
64. Peremans et al., 1981 17 (16) Mþ F Antihistamine Oral 5 Parallel Double-blind Clinical
65. Ring et al., 2001 95 (95)c Mþ F Antihistamine Oral 6 Parallel Double-blind Clinical
66. Saini et al., 2011 21 (21)c Mþ F Immunomodulator Injection 4 Parallel Double-blind Clinical
67. Wan, 2009 30 (17) Mþ F Antihistamineþ Leukotriene
receptor antagonist
Oral 4 Parallel Single-blind Clinical
68. Zuberbier et al., 2010 184 (181)c Mþ F Antihistamine Oral 4 Parallel Double-blind Clinical
Mixed population (AD and URT)
69. Henz et al., 1998 47 (11þ 28) Mþ F Antihistamine Oral 2 Parallel Double-blind Clinical
70. Monroe, 1989 17 (17) Unclear Opioid receptor antagonist Oral 1 Parallel Double-blind Clinical
Abbreviations: DMARD, disease-modifying anti-rheumatic drug; F, female; M, male.
aStudies in bold have been included in the quantitative meta-analysis.
bSample size placebo at start (numbers analyzed).
cIndicates that the numbers of patients were analyzed on the basis of modified intention to treat––e.g., including all randomized patients who received at least one dose of the study drug and/or for whom at
least one postbaseline value was available.
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DISCUSSION
This meta-analysis investigated the effect of placebo on itch in
patients with chronic itch due to AD, PSO, or URT, who
participated in clinical trials investigating regular pharmaco-
logical treatment for their skin condition and who were blindly
randomized to the placebo-control condition. Overall, itch
was significantly reduced by 24% from baseline. The ES (0.55)
was medium to large, indicating that itch can be considerably
reduced by placebo effects. Placebo effects on itch were
largest in patients with URT, followed by patients with PSO
and AD. The route of administration did not significantly
influence the effect of placebo.
The present results are generally in line with those for meta-
analyses of the effect of placebo in patients with chronic
pain––e.g., in patients with fibromyalgia pain decreased by
1.4 points out of 10 (Hauser et al., 2011), and in patients
with osteoarthritis an ES of 0.51 was found (Zhang et al., 2008)
but the ES was higher than in other meta-analyses involving
patients with various (acute) pain conditions (0.15–0.27)
(Vase et al., 2002; Hrobjartsson and Gotzsche, 2004; Vase
et al., 2009). The majority of the patients included
in the current meta-analysis had long-term itch that was
resistant to treatment, and itch was one of the main
symptoms of their dermatological condition. The relatively
Study or subgroup
Mean difference
IV, random, 95% CI
Mean difference
IV, random, 95% CIMean difference SE Total Total
After
placebo
Weight
0.60 (–0.38, 1.58)
3.0%
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Lintu et al. (2001)
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Figure 1. Forest plot of the random effects meta-analysis of the studies included in the quantitative analysis. CI, confidence interval.
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large effect of placebo on itch may be explained by the
fact that itch is highly susceptible to suggestion, as supported
by experimental research (Papoiu et al., 2011; Van Laarhoven
et al., 2011).
From a clinical point of view, the magnitude of the placebo
effect on itch (overall itch reduction of 24%) is considered a
minimally important difference in patients with URT, for
whom a cutoff for itch improvement of 4.5–5 out of 21 has
been reported (Mathias et al., 2012). It is also somewhat less
compared with the clinically important difference of X30%
defined for PSO (Mamolo et al., 2014). In clinical trials of
pain, a decrease of 24% would be characterized as a
minimally to moderately important clinical improvement
(Dworkin et al., 2009). Furthermore, the effect of placebo on
itch differed by skin condition, being largest in patients with
URT, followed by PSO and AD. The smaller effect of placebo
in patients with AD is probably because these patients
generally receive topical treatment or phototherapy
(Eichenfield et al., 2014; Sidbury et al., 2014), whereas
systemic treatment is preferred for patients with PSO or URT
(Menter et al., 2009; Maurer et al., 2013a). Consequently,
patients’ expectations of the treatment may have been more
positive in the patients with PSO and URT than in the patients
with AD. Moreover, the magnitude of the placebo effect on
itch was greater in the more recent and higher quality studies,
more often involving patients with PSO and URT, because of
improvements in study quality and in the effectiveness of the
active treatments over time, which might increase patients’
positive expectations of treatment, and hence the reduction in
itch caused by placebo (Colloca and Miller, 2011).
Although the underlying mechanisms of AD, PSO, and URT
and associated itch are largely unknown, it is clear that the
clinical manifestation, underlying pathophysiology, and effec-
tiveness of treatments differ across these conditions (e.g.,
Guttman-Yassky et al., 2011; Saini, 2014). However,
placebo effects can, depending on the patient’s expectations
and specific context, affect a wide range of brain regions and
biochemical pathways (e.g., Pollo et al., 2011). For example,
it has been shown that antinociceptive pathways can be
activated in pain and that dopamine can be released in
Parkinson’s disease (Benedetti, 2008; Pollo et al., 2011).
Similarly, it is also likely that various itch-pathways––e.g.,
mediated by histamine or substance P––can be affected by
placebo effects. More research to the mechanisms underlying
placebo effects in (different types of) itch is warranted.
The study had some limitations. First, it compared the levels
of itch at the end of placebo treatment with the levels of itch at
baseline. A no-treatment control condition would have been a
better comparator compared with the baseline levels of itch, to
exclude the possibility that the reduction in itch was due to
regression to the mean or natural course of disease (Barnett
et al., 2005; Miller and Rosenstein, 2006). However, with the
clinical trials currently available, the present approach is the
best way to investigate the effects of placebo on itch. Second,
although heterogeneity across studies was high, secondary and
sensitivity analyses did not reveal one major source of
heterogeneity––e.g., skin condition or study quality. The
random-effects model was selected to take into account the
expected heterogeneity (Hedges and Vevea, 1998). Third,
although relevant data for the placebo condition were not
fully available for several studies, we found no indications for
publication bias in the funnel plot. Moreover, potential
publication bias would probably be in favor of active
treatment conditions, so that the present study might have
underestimated the magnitude of placebo effects on itch.
Finally, earlier studies of the analgesic effect of placebo have
shown that placebo effects are stronger in mechanistic studies
than in clinical trials (Vase et al., 2002), probably because of
the certainty of the suggestions given, suggesting that the
current study does reflect a rather conservative indication of
the magnitude of placebo effects on itch. Future clinical studies
would be recommended to report on the underlying
pathophysiology, as well as the extent to which the itch-
reducing effects of the treatment had been emphasized.
In conclusion, placebo would appear to have a substantial
effect in the treatment of itch in dermatological patients with
chronic itch. As it is recognized that both the certainty of the
suggestions given along with treatment and conditioning prin-
ciples affect the efficacy of that treatment (Vase et al., 2002;
Pacheco-Lopez et al., 2006), making use of the placebo effect in
an open manner and under strict ethical conditions (Colloca
and Miller, 2011; Rief et al., 2011) might improve the efficacy
of itch-reducing treatments in clinical dermatological practice.
METHODS
Protocol and registration
The meta-analysis was performed according to the PRISMA Statement
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
(Moher et al., 2009) and the recommendations of the Cochrane
Collaboration (Higgins and Green, 2009) (www.cochrane-handbook.
org), within the (word) limitations of the journal. The study protocol
has been published in the Prospero registry (CRD42013006053).
Information sources and searches
The databases Pubmed, PsycInfo, Embase, and the Cochrane Library
were searched from inception until 6th July 2014 by the first author,
using the following key terms: ‘‘itch’’ or ‘‘pruritus’’ and ‘‘placebo’’,
‘‘sham’’ or ‘‘dummy/ies’’; animal studies were excluded. In the
Supplementary Table S1 online, the specific MeSH terms and
Boolean operators used for Pubmed are shown (for the other three
databases, comparable terms, e.g., MeSH and EMTREE, were used). In
addition, the references of eligible studies and studies that cited the
eligible studies were hand-searched for relevant articles.
Eligibility criteria
The titles and abstracts of the identified studies were screened by the
first author according to the following criterion: the study had to be an
original randomized placebo-controlled trial investigating regular
systemic medication in patients with a chronic dermatological condi-
tion associated with chronic itch––namely, AD, PSO, or URT. The
eligibility criteria are described in more detail in the Supplementary
Material online.
Study selection
The full text of potentially eligible studies, including those for which
there was any doubt about the eligibility based on the abstract, was
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retrieved via online university libraries or the authors. The eligibility
of the full-text articles was evaluated by the first author; a second
reviewer assisted if there was doubt about article eligibility. Dis-
crepancies were resolved by discussion with a third reviewer.
Data collection process and data items
The following data were extracted from the included studies by the
use of a standardized form, developed prior to the meta-analysis:
population and participant demographics; details of the active and
placebo interventions; details of the study design; itch outcome
measures; and relevant data for meta-analysis––i.e., sample size,
mean, and SD of the (change of the) measurements before and after
placebo. The data were extracted by two review members. Ambi-
guities were identified and rechecked, and consensus was achieved
through discussion. If needed, a third review member reviewed the
data to reach consensus. Missing data were requested from study
authors.
Risk of bias in individual studies and across studies
The quality of all included studies was assessed using the Cochrane
risk of bias tool version 5.0.2. The following categories were
evaluated for each study: Sequence generation, Allocation conceal-
ment, Blinding of participants, personnel, and outcome assessors
(as one category), Incomplete outcome data, Selective outcome
reporting, and Other sources of bias (with a main focus on drop-out
rate, baseline differences across treatment groups). These categories
were scored with yes (i.e., low risk of bias), no (i.e., high risk of bias),
or unclear risk of bias. Two review members independently assessed
the quality of the included studies using this tool. Disagreements
for particular studies were resolved through discussion, with the
involvement of a third review member where necessary. Poor-quality
studies (i.e., for which at least one risk of bias category was scored
high) were identified, for which sensitivity analyses were conducted
(see section Sensitivity analyses). In order to assess the risk of bias
across studies, the funnel plot was inspected for the presence of
publication bias.
Summary measures
The change (with SD or SE) in itch score from baseline to the end of
placebo treatment was the preferred outcome to be collected. If not
available, the itch scores at baseline as well as at the end of placebo
treatment were retrieved. If multiple outcome data for itch were
reported, the measurement that included the relevant data for the
meta-analysis was selected, with a preference for actual itch scores
obtained in the clinic (i.e., actual itch scores) over retrospective self-
report or diary assessments. If only experimentally induced itch was
investigated, then preference was given to data for itch induced at
lesional skin with a commonly used stimulus such as histamine. In
cross-over trials, only data from patients randomized first to the
placebo condition were included (see also Vase et al., 2002).
Scientifically admissible numerical data were recorded by the first
author and then checked for completeness and correctness by another
author. Data displayed in graphs were extracted by two review
authors. If relevant data could not be extracted from the publication,
the authors of that study were asked to provide the remaining data.
The authors of 36 studies were contacted and contact details of 5
authors were unavailable. Requested information could be provided
from four studies.
Analyses
The exact procedures for the synthesis of results and main analysis, as
well as secondary and sensitivity analyses, are described in the
Supplementary Material online.
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